Abstract:The COVID-19 pandemic disrupted access to cancer treatment. 1 COVID-19–related disruptions in treatment may have disproportionately affected individuals who experienced a high burden of COVID-19–related disease. 1 Our objective was to evaluate cancer treatment discontinuations (TDs) among patients with cancer who received a diagnosis of SARS-CoV-2 during their cancer treatment planning. Data for this cross-sectional study were obtained from the American Society of Clinical Oncology Survey on COVID-19 in Oncology Registry 2 (March 2020 to September 2022). Participating clinics included patients according to 2 eligibility criteria: (1) confirmed SARS-CoV-2 infection and (2) engagement in care at the time of infection. TD was defined as discontinued or canceled treatment with no plans of restart as reported by the clinic. Median (IQR) time between COVID-19 diagnosis date and the date TD status was ascertained was 2 (0-5) months. Owing to the descriptive nature of this analysis, we did not include an adjustment for multiple comparisons. 3 The study was reviewed by the Scientific Review Committee at Moffitt Cancer Center and was deemed as nonhuman participants research. The study was reported in accordance with the STROBE reporting guidelines. 4 Further details regarding the study methods have been previously published 2 and are shown in Supplement 1. The study population included 3812 patients (3125 patients [82%] aged ≥50 years; 2286 female [60%]; 2595 non-Hispanic White patients [68%]; 443 Hispanic patients [12%]; and 3290 patients living with ≤2 comorbidities [86%]) (Table). Overall, the prevalence of TD was 5.3% (200 of 3182 patients), with 3454 (90.6%) scheduled for drug-based therapy, 361 (9.5%) for radiation, 216 (5.7%) for surgery, and 30 (0.8%) transplant or cellular therapy. Controlling for other factors, non-Hispanic Asian patients had a much higher likelihood of experiencing cancer TD vs their non-Hispanic White counterparts (adjusted prevalence ratio [aPR], 1.62; 95% CI, 1.13-2.32) (Figure). Clinical factors associated with elevated likelihood of cancer TD included a higher (≥3) Eastern Cooperative Oncology Group score (adjusted prevalence ratio [aPR], 2.61; 95% CI, 1.12-4.36) and diagnosis with a gastrointestinal cancer (aPR, 2.13; 95% CI, 1.29-3.52). Severe COVID-19 outcomes were associated with a higher likelihood of cancer TD. Patients with stable cancer at COVID-19 diagnosis were less likely to experience cancer TD compared with those with progressing cancer (aPR, 0.51; 95% CI, 0.36-0.71). To our knowledge, this cross-sectional study of cancer treatment TD is novel because we focus on a population of patients with cancer who experienced severe interruptions in care during the COVID-19 pandemic. Importantly, TD was more likely to occur during the early phases of the pandemic, which may be due to multiple reasons such as availability of COVID-19 vaccination, and changes in response of health care systems once safety protocols were established. 1 We found that non-Hispanic Asian patients with cancer were most likely to experience TD. Multiple factors may have led to this racial inequity in receipt of cancer treatment, including difficulties leveraging telehealth due to language barriers among older Asian patients and the higher likelihood of hospitalization and death due to COVID-19 compared with White adults. 5 Clinical factors identified pertinent to cancer TD, such as gastrointestinal cancer diagnosis or severe COVID-19 disease, is similar to prior analysis that focused on any cancer treatment delays of at least 14 days. 6 Of note, cancer TD was less likely to occur among patients with stable cancer vs those with progressing cancers. This may suggest that patients already engaged in care were able to continue treatment. An important limitation of our data is that the type of cancer treatment (ie, adjuvant, palliative) was not available, which may have affected the risk or benefit for completing treatment. Nonetheless, our findings suggest long-term consequences of cancer treatment cancellations should be monitored to identify any potential exacerbations in inequities in cancer outcomes due to the COVID-19 pandemic. Accepted for Publication: March 17, 2024. Published: May 23, 2024. doi:10.1001/jamanetworkopen.2024.11859 Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2024 Islam JY et al. JAMA Network Open . Corresponding Author: Jessica Y. Islam, PhD, MPH, Center for Immunization and Infection in Cancer, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612 (jessica.islam@moffitt.org). Author Contributions: Dr Islam had full access to all of the data in the study and takes responsibility -Abstract Truncated-

Continuity of care for patients with de novo metastatic cancer during the COVID‐19 pandemic: A population‐based observational study

Impact of the COVID‐19 pandemic on the in‐hospital diagnostic pathway of breast and colorectal cancer in the Netherlands: A population‐based study

Impact of the COVID-19 Pandemic on Colorectal Cancer Care in the Netherlands: A Population-based Study

Impact of the COVID-19 Outbreak—Delayed Referral of Colorectal and Lung Cancer in Primary Care: A National Retrospective Cohort Study

Perceived Care and Well-being of Patients With Cancer and Matched Norm Participants in the COVID-19 Crisis: Results of a Survey of Participants in the Dutch PROFILES Registry

The Impact of the COVID-19 Pandemic on Time to Treatment in Surgical Oncology: A National Registry Study in the Netherlands

Impact of COVID-19 on patients with metastatic breast cancer: REthink Access to Care and Treatment survey results

Cancer incidence, stage shift and survival during the 2020 COVID‐19 pandemic: A population‐based study in Belgium

The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands

Changes in New Patient Consultations During the COVID-19 Pandemic at a Canadian Comprehensive Cancer Center

Incidence of gynaecological cancer during the COVID-19 pandemic: A population-based study in the Netherlands

Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality

Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study

The impact of cancer metastases on COVID‐19 outcomes: A COVID‐19 and Cancer Consortium registry‐based retrospective cohort study

A multi-centre survey reveals variations in the standard treatments and treatment modifications for head and neck cancer patients during Covid-19 pandemic

Rising incidence of late stage breast cancer after COVID-19 outbreak. Real-world data from the Italian COVID-DELAY study

Survival Among Patients With High-Risk Gastrointestinal Cancers During the COVID-19 Pandemic

Impact of the COVID-19 Pandemic on Patient-Reported Outcomes of Breast Cancer Patients and Survivors

Impact of COVID‐19 on cancer incidence, presentation, diagnosis, treatment and survival in Northern Ireland

Impact of COVID-19 on Incidence, Treatment, and Survival of Patients with Hepatocellular Carcinoma in the Netherlands

Patients With Cancer and COVID-19 Who Discontinued Cancer Treatment